Loading clinical trials...
Loading clinical trials...
Keratinocyte Growth Factor - Promoting Thymic Reconstitution and Preventing Autoimmunity After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis
Conditions
Interventions
Palifermin
Alemtuzumab
Locations
1
United Kingdom
Addenbrooke's Hospital
Cambridge, Cambridgeshire, United Kingdom
Start Date
June 1, 2012
Primary Completion Date
August 1, 2017
Completion Date
October 1, 2017
Last Updated
April 30, 2019
NCT07225504
NCT06276634
NCT06809192
NCT05359653
NCT07426991
NCT07376772
Lead Sponsor
Cambridge University Hospitals NHS Foundation Trust
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions